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INTRODUCTION
to detect a 2-fold change between these groups (90% power, two-sided test, type I error 0.05).
1 For security, we included 14 subjects in each of these groups. Additionally, we randomized two 2 groups of 8 volunteers without MXF, but with DAV132 or CTL to study secondary objectives 3 (DAV132 safety and intestinal microbiota composition). 4 As preplanned for the primary objective, comparison of log(AUCD1-D16) of free MXF fecal 5 concentrations, in groups treated with MXF+DAV132 and MXF alone, was performed using a 6 general linear model. AUCD1-D16 were calculated by the trapezoidal method using the actual 7 time of stool emission and the results were expressed as geometric means of AUCD1-D16 and 8 coefficient of variation. For MXF plasma concentrations, comparisons of log(AUC0-24h) and 9 log(Cmax), in groups treated with MXF+DAV132 and MXF alone, were perfomed using a 10 general linear model. AUC0-24h was calculated by the trapezoidal method. Statistical analysis of 11 clinical and pharmacokinetic data were performed using the SAS 9.4 software (SAS Institute, 12 Cary, NC, USA).
13
Metagenomic methods and analysis 14 Analysis of metagenomic data was exploratory and not prespecified. Essentially, total fecal 15 DNA was extracted as described [24, 25] 
Adsorption of antibiotics by activated charcoal ex vivo.
1 To mimic at best the adsorption of antibiotics onto activated charcoal in the gut we used cecal 2 medium that had been obtained from extemporaneously euthanised pigs, and stored at -80°C 3 since. Antibiotics (400 µg/mL), and activated charcoal (4 mg/mL) obtained from DAV132 4 deformulated by incubation for 30min at 37°C in 50 mM sodium phosphate buffer pH 7.5 5 containing 80 nM NaCl, were independently pre-incubated with cecal medium (1:1 v:v) for 2h 6 at 37°C. Then, the two pre-incubation reactions were mixed and further incubated for 3h at 7 37°C with gentle agitation. When the tested antibiotic was sensitive to β-lactamases, 8 endogenous enzymes were inactivated by heating at 70°C for 1h. Samples were centrifuged 9 3minX19,890 g, and the concentrations of non-adsorbed antibiotics in the supernatant were 10 quantified in triplicate using a microbiological assay [29] . Table 1 ). When adjusting for each main individual characteristic of the volunteers MXF+DAV132 than in those receiving MXF alone (q=4.10 -7 ), and not significantly different 
Ex-vivo adsoption of other antibiotics 1
To assess whether DAV132 could also protect against antibiotics other than MXF routinely 2 used in the clinic, we examined the capacity of the activated charcoal released from DAV132 to 3 adsorb them under ex vivo conditions, i.e. in pig cecal medium (Table 2) . Among the 14 4 antibiotics routinely used in clinic tested, 13 were adsorbed to an extent of at least 95% by the 5 charcoal after 3-5h of contact with deformulated DAV132. Only amoxillin was a little less 6 adsorbed, to the extent of 92%. 7 8 1 address directly the efficacy of DAV132 to protect patients againt immediate consequences of 2 antibiotic treatments such as C. difficile colitis. However, we recently published pre-clinical 3 results in hamsters that suggest that such might well be the case [31] . Second we did not 4 address the possibility that DAV132 might interfere with other drugs that could be taken 5 concomitantly for therapeutic purposes by patients treated with antibiotics. This was far beyond 6 the purpose of the current study but will have to be determined before testing the product in 2 max] were 11.63 [9.50 ; 13.24] for MFX, 15.34 [14.10 ; 16.62] for MXF+DAV132, 15.66 3 [14.91 ; 17.28] for DAV132 and 15.59 [14.88 ; 18.25] 
